Average loss at the highest dose was about 22.5 percent of body weight over 72 weeks in adults with obesity and no diabetes
The nine tissue systems now documented in the preclinical literature were not predicted by computational models or receptor-binding assays at the outset they were identified sequentially as researchers in different laboratories independently tested the compound against different experimental injury models and consistently found meaningful effects
2026 ADA Standards Update: GLP-1 RA in Diabetes Treatment Algorithms The 2026 ADA Standards of Care mark a continued evolution in diabetes pharmacotherapy, more formally incorporating GLP-1 receptor agonists into organ-specific treatment algorithms
For now, resistance training, appropriate nutrition, regular movement and medical supervision remain the most practical foundations
According to a recent press release, tirzepatide was non-inferior to dulaglutide, an agent with proven cardiovascular prevention benefits, in preventing MACE-3, defined as cardiovascular death, nonfatal heart attack, or nonfatal stroke
GLP-1s have done a great service in bringing the conversation around obesity back to lifestyle and nutrition
